Loxiglumide

SKU: orb1222890

Description

Loxiglumide is a potent, orally active, and selective CCK-A receptor antagonist which stimulates calorie intake and hunger feelings in humans. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secretions and emptying. Intravenous administration of loxiglumide antagonized the CCK-induced reduction of gastric emptying in rats, acceleration of intestinal transport in mice, increase in ileal motility in rabbits, gallbladder contraction in guinea pigs and acceleration of gallbladder emptying in mice.

Key Properties

• CAS Number: 107097-80-3
• MW: 461.38
• Purity: >98% (HPLC)
• Formula: C₂₁H₃₀Cl₂N₂O₅
• SMILES: CCCCCN(CCCOC)C(=O)C(CCC(=O)O)NC(=O)c1cc(c(cc1)Cl)Cl
• Target: CCK
• Solubility: DMSO : ≥ 150 mg/mL; 325.11 mM

Bioactivity

• In Vivo:
  The effects of pancreatic rest by oral administration of CCK-1 receptor antagonist Loxiglumide and pancreas stimulation are investigated via endogenous CCK release induced by po protease inhibitor camostat on the recovery of pancreatic secretory function, and biochemical and histological changes of the pancreas after acute hemorrhagic pancreatitis. Oral administration of CCK-1 receptor antagonist Loxiglumide with a dose of 50 mg/kg body weight inhibits pancreatic exocrine secretion for more than 12 h. Thus, every 12-h administration of Loxiglumide might have completely blocks the effect of endogenously released CCK on the pancreas (pancreatic rest).

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CR-1505 | Loxiglumide, brand name: Loxizin.

Quick Database Links

Gene Symbol

CCK